-+ 0.00%
-+ 0.00%
-+ 0.00%

Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026

Benzinga·10/19/2026 11:02:49
Listen to the news

Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumors

Company to host webcast on Saturday, October 24, 2026, at 6 p.m. CEST / 12 p.m. EDT

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (NASDAQ:PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced that updated clinical data for zolucatetide in patients with desmoid tumors will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.

The oral presentation will report data from a June 22, 2026, data cutoff, including data from both the dose escalation and dose optimization portions of the ongoing Phase 1/2 trial. Dose optimization in the desmoid tumor-specific cohort is designed to inform selection of the dose and schedule to be carried forward into the planned registrational Phase 3 trial of zolucatetide in patients with desmoid tumors.

Zolucatetide has received both Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors.